MADISON, Wis. — Wisconsinite and business owner Lynn McFee said an innovate screening test and groundbreaking technology may have helped save her life. 


What You Need To Know

  • Lynn McFee, owner of McFee on Main boutique in Mount Horeb, Wis., conquered colon cancer after opting for the FDA-approved Cologuard test for screening
  • Following a positive result, McFee underwent surgery and chemotherapy. She said she was grateful for the support she received and the positive outcome she experienced
  • To commemorate four years of clean scans, McFee was offered a special tour of Exact Sciences' facilities in Madison, gaining insight into the advanced automation processes behind Cologuard
  • McFee's journey serves as a testament to the importance of early detection and the impact of innovative technologies like Cologuard in the fight against colon cancer

McFee is the owner of McFee on Main boutique in Mount Horeb, Wis. She ventured into entrepreneurship with her boutique after a successful career with Ralph Lauren. She said she cherishes her business as “a little gem” close to her heart.

When she turned 60, McFee decided to take control of her health and opted for the non-invasive FDA-approved Cologuard test for colon cancer screening.

“Do it at home. My privacy, my deal, I can do Cologuard,” she said of the test.

The test came back positive, prompting further investigation that led to the discovery of a slow-growing cancer. McFee underwent surgery and chemotherapy. She said she was grateful for the support she received and the positive outcome she had.

“Everything’s manageable. You just have to put your mind to it,” McFee said of her journey.

She said that mindset is what helped guide her through the challenges of her cancer.

McFee’s scans for cancer have now been clear for four years. It’s a significant milestone for her. To commemorate the achievement, she was offered a special tour of Exact Sciences’ facilities in Madison, the company behind Cologuard.

During the tour, McFee witnessed the advanced automation processes involved in processing the Cologuard kits.

“You can see there’s a high level of automation,” said Zach Swensen, clinical lab director at Exact Sciences. “We’re constantly striving to enhance the sensitivity and accuracy of Cologuard.”

Swensen said the company is committed to improving cancer detection through innovation.

McFee said her journey with battling cancer serves as a testament to the importance of early detection and the impact of innovative technologies like Cologuard.

“As someone with no family history of cancer, I was really blessed that I guess the timing was right,” McFee reflected.